ASMB logo

Assembly Biosciences Inc. (ASMB)

$22.50

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ASMB

Market cap

$460737990

EPS

1

P/E ratio

19.4

Price to sales

6.4

Dividend yield

--

Beta

1.263409

Price on ASMB

Previous close

$21.29

Today's open

$21.28

Day's range

$21.15 - $22.60

52 week range

$19.20 - $39.71

Profile about ASMB

CEO

Jason A. Okazaki

Employees

73

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

20477244

Issue type

Common Stock

ASMB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ASMB

Assembly Biosciences, Inc. (ASMB) Presents at UBS Global Biopharma Conference 2026 Transcript

Assembly Biosciences, Inc. ( ASMB ) UBS Global Biopharma Conference 2026 November 17, 2026 7:00 AM EST Company Participants Jason Okazaki - CEO, President & Director Anuj Gaggar - Chief Medical Officer Katie Kitrinos - Senior VP of Preclinical Research & Development Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. Welcome to UBS Biopharma Conference in London.

news source

Seeking Alpha • Nov 17, 2026

news preview

Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates

– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –

news source

GlobeNewsWire • Nov 12, 2026

news preview

Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Assembly Biosciences to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:

news source

GlobeNewsWire • Nov 2, 2026

news preview

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –

news source

GlobeNewsWire • Oct 29, 2026

news preview

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction

news source

GlobeNewsWire • Oct 5, 2026

news preview

New Strong Buy Stocks for September 17th

MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.

news source

Zacks Investment Research • Sep 17, 2026

news preview

Best Momentum Stocks to Buy for September 17th

MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.

news source

Zacks Investment Research • Sep 17, 2026

news preview

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.

news source

GlobeNewsWire • Sep 10, 2026

news preview

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

news source

Zacks Investment Research • Sep 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Assembly Biosciences Inc.

Open an M1 investment account to buy and sell Assembly Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ASMB on M1